Combination Anlotinib and Sintilimab Exhibits Antitumor Activity in Advanced Endometrial Cancer
Nearly three-quarters of patients responded to treatment.
News
Latest News
Reducing Maintenance Produced ‘Outstanding’ Survival Outcomes in Pediatric Acute Lymphoblastic Leukemia
Survival rates were similar whether maintenance was given every 12 weeks or every 4 weeks.
Gemtuzumab Ozogamicin Can Improve Outcomes in Pediatric KMT2A-Rearranged Acute Myeloid Leukemia
Gemtuzumab ozogamicin improved event-free survival and disease-free survival.
Genomic Signature May Identify Breast Cancer Patients Who Can Safely Forgo Adjuvant Radiotherapy
The signature was prognostic for locoregional recurrence.
Chemotherapy Doesn’t Increase the Risk of COVID-19 or Related Death in Patients with Breast Cancer, Study Suggests
Rates of SARS-CoV-2 infection and COVID-19-related death were similar among patients receiving cytotoxic and non-cytotoxic therapy.
Endocrine Therapy Proves Noninferior to Chemotherapy in HR+, HER2+ Metastatic Breast Cancer
Endocrine therapy was associated with fewer adverse events.
Mobile Wearable Devices Show Some Sleep Disturbances During Multiple Myeloma Treatment
Younger patients had a significant decrease in sleep time on days they received dexamethasone.
Age and Stage at Breast Cancer Diagnosis Don’t Account for Racial Disparities in Distant Metastases
Black patients were more likely than White patients to have distant metastases.
Pasireotide Plus Everolimus Improves PFS in Advanced Neuroendocrine Tumors of the Lung or Thymus
The median PFS was 8.5 months in the pasireotide arm, 12.5 months in the everolimus arm, and 16.5 months in the combination arm.
Bone-Protecting Agents Reduce Fractures Associated With Treatment in Metastatic Castration-Resistant Prostate Cancer
The cumulative incidence of bone fractures was below 5% in BPA recipients.
Final Results Support Pembrolizumab as Standard of Care in MSI-H/dMMR Metastatic Colorectal Cancer
Pembrolizumab improved progression-free survival but not overall survival.
Iberdomide-Based Regimens Show Promise in Relapsed/Refractory Multiple Myeloma
The median duration of response was 35.7 weeks with iberdomide, bortezomib, and dexamethasone compared with not reached in patients who received iberdomide, daratumumab, and dexamethasone or iberdomide, bortezomib, and carfilzomib
Relapsed, Refractory Follicular Lymphoma: CAR T-Cell Therapy Shows Promise
In patients who had received at least 2 prior therapy lines, the overall response rates were 49.9% in SCHOLAR-5 vs 94.2% in ZUMA-5.
DLBCL: Naratuximab Shows Promise Among Patients With Relapsed/Refractory Disease
The overall response rate was 44.7% after a median follow-up of 15 months.
Long-Term Follow-Up Data Support Adding Daratumumab to Lenalidomide/Dexamethasone in Transplant-Ineligible MM
The median progression-free survival was not reached in the D-Rd group compared with 34.4 months in the Rd group.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...